Global Paradise System US Post Approval Study
Eligible age
18+ yrs
Accepts
All genders
Locations
22 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.
Sponsor: ReCor Medical, Inc.
You may qualify if…
- ✓ Signed and dated study informed consent
- ✓ Documented history of hypertension
- ✓ Documented history of prior or current antihypertensive medication(s)
- ✓ Mean seated office systolic BP at screening ≥ 140 mmHg
- ✓ Mean pre-procedure home systolic BP of ≥ 135 mmHg
- ✓ Estimated glomerular filtration rate (eGFR) of ≥30 mL/min/m2
- ✓ RADIANCE CAP patients must provide signed and dated informed consent for inclusion in long-term follow-up. No other criteria are required for inclusion.
You may not qualify if…
- ✕ Patients who meet the following will be excluded from participation:
- ✕ Patient lacks appropriate renal anatomy for any treatment with the Paradise Catheter
- ✕ Patient under the age of 18 years old at the time of consent
- ✕ Patient is pregnant
- ✕ Patients with transplanted kidney
- ✕ Presence of abnormal kidney (or secreting adrenal) tumors
- ✕ To confirm eligibility for treatment with the Paradise System, the following contraindications listed in the IFU may be determined at the time of procedure prior to treatment:
- ✕ Renal arteries with diameter \< 3mm and \> 8mm
Where it's recruiting
Sacramento · Santa Monica
Aurora
Bridgeport
Gainesville · Miami · Pensacola · Tampa
Marietta
Springfield
Wichita
New Orleans
Boston
Detroit
Coon Rapids
Kansas City
Source: ClinicalTrials.gov · NCT06297291 · last updated 2026-05-07